SCNIScinai Immunotherapeutics Ltd.vs its industry peers
A metric-by-metric comparison of Scinai Immunotherapeutics Ltd. against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SCNI본 종목 | $33.2B#1 | 597.5x#1 | 4091.8x#1 | 25290.8x#1 | 99.2%#3 | -273.2%#3 | -575.3%#1 | -102.5%#1 | -110.5%#1 | — | — | — |
| MEOBF | — | — | — | — | 191.4%#2 | -16.1%#2 | — | — | — | — | — | — |
| TCRX | — | — | — | — | 266.7%#1 | -1.8%#1 | -1315.4%#2 | -188.0%#2 | -8271.2%#2 | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. 이 표는 생성 중 시간이 초과되어 그룹의 일부만 포함합니다. 순위는 표시된 행 내에서만 유효하며 곧 채워집니다. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice